Chandrashekar Bohra

Chandrashekar Bohra

Auto-generated profile, based on publicly available information

Chandrashekar Bohra

Division of Cardiology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 April 2018 in Medicine
Verified
Journal Article
Open access
DSDoosup Shin
Doosup Shin
CBChandrashekar Bohra
Chandrashekar Bohra
KKKullatham Kongpakpaisarn
Kullatham Kongpakpaisarn
Although the Friedewald method has been used as the clinical standard to estimate low-density lipoprotein cholesterol (LDL-C) levels, a novel method with better accuracy was suggested and is now being adopted in real practice. We investigated the effect of this novel method on determining the eligibility for statin treatment for primary prevention in the United States. In this cross-sectional study, we determined the discordance in the statin-eligible population for primary prevention according to the 2 different LDL-C estimating methods based on the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines. Using data from the National Health and Nutrition Examination Survey 2005–2014, we included 5302 nationally representative US adults aged between 40 and 75 years without history of atherosclerotic cardiovascular disease (ASCVD). Sampling weights were used in all statistical analyses to account for complex sampling design and nonresponse. If the Friedewald method is replaced by the novel method for analysis of the fasting samples, 0.2% (95% confidence interval [CI], 0.0–0.8) and 0.4% (95% CI, 0.3–0.6) of the population would no longer be eligible or would become newly eligible for statin treatment, respectively. Among the individuals with a TG level ≥150 mg/dL and LDL-C level estimated using the Friedewald method <70 mg/dL, 11.6% (95% CI, 4.0–29.3) would become newly eligible for the statin treatment when using the novel method. The use of the novel method for estimating LDL-C instead of the Friedewald method would be associated with a small net increase in statin eligible/needed US adults for primary prevention based on the 2013 ACC/AHA guidelines. Reassessment of individuals’ statin eligibility using the novel method may be beneficial, particularly when their TG level is 150 mg/dL or higher and LDL-CF level is lower than 70 mg/dL.

1 May 2016 in Infectious Diseases in Clinical Practice
Verified
Journal Article
Closed access
GGGanesh Mbbs Gajanan
Ganesh Mbbs Gajanan
CBChandrashekar Mbbs Bohra
Chandrashekar Mbbs Bohra
SNSowmya Nanjappa
Sowmya Nanjappa
JGJohn N. Md Greene
John N. Md Greene
The association of chronic inflammation with a variety of epithelial malignancies has been recognized for centuries. Infection is one of the most important causes of cancer worldwide, causing approximately 1 in 5 malignancies. It has been well known that chronic infections lead to induction of chronic inflammation, which can lead to the development of squamous cell carcinoma (SCC). In addition, SCC is more likely to develop in injured or chronically diseased skin. Chronic infections with bacteria, viruses, fungi, and protozoa have been associated with development of SCC. We present a unique case of an abdominal wall ulcer complicated by recurrent infections, which ultimately developed into SCC.

26 June 2024 in Structural Heart
Verified
Journal Article
Open access
CBChandrashekar Bohra
Chandrashekar Bohra
FAFederico M. Asch
Federico M. Asch
SLStamatios Lerakis
Stamatios Lerakis
SLStephen H. Little
Stephen H. Little
BRBjörn Redfors
Björn Redfors
GSGregg W. Stone
Gregg W. Stone
The implications of pulmonary vein (PV) flow patterns in patients with heart failure (HF) and mitral regurgitation (MR) are uncertain. We examined PV flow patterns in the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (COAPT) trial (NCT01626079), in which patients with HF and moderate-to-severe or severe functional MR were randomized to transcatheter edge-to-edge repair (TEER) with the MitraClip device plus guideline-directed medical therapy (GDMT) vs. GDMT alone. We sought to evaluate the prognostic utility of baseline PV systolic flow reversal (PVSFR) in HF patients with severe MR and to determine whether the presence of PVSFR can discriminate patients most likely to benefit from TEER in COAPT trial patients. Patients were categorized by the echocardiographic core laboratory-assessed baseline presence of PVSFR. Two-year outcomes were examined according to PVSFR and treatment. Baseline PV flow patterns were evaluable in 526/614(85.7%) patients, 48.9% of whom had PVSFR. Patients with PVSFR had more severe MR, reduced stroke volume and cardiac output, greater right ventricular dysfunction, and worse hemodynamics. By multivariable analysis, PVSFR was not an independent predictor of 2-year all-cause death, or heart failure hospitalization (HFH). The reductions in the 2-year rates of all-cause death and HFH with TEER compared with GDMT alone were similar in patients with and without PVSFR (Pinteraction = 0.40 and 0.12, respectively). The effect of TEER on improving Kansas City Cardiomyopathy Questionnaire scores and 6-minute walk distance were also independent of PVSFR. In the COAPT trial, PVSFR identified HF patients with severe MR and more advanced heart disease. Patients with and without PVSFR had consistent reductions in mortality, HFH, and improved quality-of-life and functional capacity after TEER. ClinicalTrial.gov IdentifierNCT01626079.

1 May 2021 in JACC
Verified
Journal Article
Closed access
CBChandrashekar Bohra
Chandrashekar Bohra
PLPersio Lopez Loyo
Persio Lopez Loyo
ANAdrian Nugent
Adrian Nugent
VGVaani Garg
Vaani Garg

19 June 2021 in Case Reports in Medicine
Verified
Journal Article
Open access
PDF file
AMAdithya T. Mathews
Adithya T. Mathews
AMAbu-Sayeef Mirza
Abu-Sayeef Mirza
CBChandrashekar Bohra
Chandrashekar Bohra
AMAkshay G. Mathews
Akshay G. Mathews
PRPhilip Ritucci-Chinni
Philip Ritucci-Chinni
RBRichard Bowerman
Richard Bowerman
Cardiac amyloidosis is a condition when amyloid fibers are deposited in the extracellular space of the heart causing tachyarrhythmias, heart failure, or sudden cardiac death. We present a 71-year-old woman presenting with dyspnea on admission. Echocardiogram revealed diastolic heart failure and left ventricular hypertrophy with strain pattern concerning for an infiltrative process. She was discharged with diuretic therapy and scheduled for a cardiac magnetic resonance imaging. One week after discharge, she was readmitted with progressive shortness of breath and syncope. She was found to be in shock and had multiple episodes of cardiac arrest with both ventricular tachycardia and pulseless electrical activity. She developed electrical storm and eventually passed within 24 hours. Autopsy revealed gross cardiomegaly and left ventricular hypertrophy with Congo red staining revealing amyloid fibrils with apple-green birefringence. This case demonstrates the rapid progression of cardiac amyloidosis from acute-onset diastolic heart failure to uncontrollable ventricular tachycardia, and eventually death. We review the literature regarding multiple diagnostic modalities that facilitate the confirmation of cardiac amyloidosis.